Published in Ther Clin Risk Manag on June 01, 2007
Stretta: a valuable endoscopic treatment modality for gastroesophageal reflux disease. World J Gastroenterol (2014) 0.84
An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol (2010) 0.77
In vitro effect of pantoprazole on lower esophageal sphincter tone in rats. World J Gastroenterol (2011) 0.77
Impact of PPIs on patient focused symptomatology in GERD. Ther Clin Risk Manag (2008) 0.76
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol (2006) 12.80
Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA (2001) 8.40
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
Barrett's esophagus. N Engl J Med (1986) 3.62
Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology (1988) 3.51
An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut (1999) 3.45
Polypharmacy and prescribing quality in older people. J Am Geriatr Soc (2006) 3.39
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer (2001) 3.02
Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med (2004) 2.67
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 2.64
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol (1998) 2.44
The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med (1998) 2.33
Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol (2003) 2.21
Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol (2007) 2.07
Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ (2003) 2.04
Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology (2000) 1.94
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther (2003) 1.91
The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med (2001) 1.88
Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology (2004) 1.82
Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol (2000) 1.81
Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol (1993) 1.75
The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut (2001) 1.70
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol (1999) 1.65
Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl (1996) 1.63
Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther (2004) 1.61
Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev (2005) 1.58
Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med (2003) 1.57
The long-term natural history of gastroesophageal reflux disease. J Clin Gastroenterol (2006) 1.52
40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol (2004) 1.50
Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol (1986) 1.35
Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther (2003) 1.35
Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol (2000) 1.35
Proton pump inhibitors and acid-related diseases. Pharmacotherapy (1997) 1.34
Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs (2003) 1.34
Laparoscopic surgery for gastro-oesophageal reflux: beyond the learning curve. Br J Surg (1996) 1.33
Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf (2006) 1.32
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut (1996) 1.28
Prevalence of gastroesophageal reflux in elderly patients in a primary care setting. Am J Gastroenterol (1991) 1.27
Associations between different forms of gastro-oesophageal reflux disease. Gut (1997) 1.21
Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med (1999) 1.13
Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl (1999) 1.13
Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut (1997) 1.13
The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther (2000) 1.10
Escalating polypharmacy. QJM (2006) 1.09
Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus (1997) 1.08
Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther (1990) 1.08
Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) (2000) 1.05
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs (2003) 1.04
Health-related quality of life in primary care patients with gastroesophageal reflux disease. Ann Pharmacother (1999) 1.03
Esophagitis: incidence and risk of esophageal adenocarcinoma--a population-based cohort study. Am J Gastroenterol (2006) 1.03
Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol (1998) 1.03
Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease? Am Surg (1997) 1.02
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (1999) 0.99
Safety of proton pump inhibitors--an overview. Aliment Pharmacol Ther (1994) 0.96
Symptoms of gastro-oesophageal reflux disease in elderly people. Age Ageing (1991) 0.95
Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol (1997) 0.94
Esophagitis is a major cause of upper gastrointestinal hemorrhage in the elderly. Scand J Gastroenterol (1997) 0.92
Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications. Am J Gastroenterol (2000) 0.92
Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol (1997) 0.92
[Prevalence of gastro-oesophageal reflux disease in general practice]. Dtsch Med Wochenschr (2002) 0.92
Relationship between severity and symptoms of reflux oesophagitis in elderly patients in Japan. J Gastroenterol Hepatol (1998) 0.92
The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol (1997) 0.91
Endoscopic therapy for GERD--baking, sewing, or stuffing: an evidence-based perspective. Rev Gastroenterol Disord (2003) 0.89
Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol (2000) 0.88
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther (2005) 0.88
Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr (2006) 0.87
Progress with proton pump inhibition. Yale J Biol Med (1994) 0.87
The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review. Pharmacoeconomics (2003) 0.87
Current understanding of the mechanisms of gastro-oesophageal reflux disease. Drugs (2006) 0.86
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther (2003) 0.85
Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. Dis Esophagus (2006) 0.83
Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther (2004) 0.83
Management of patients with symptomatic gastroesophageal reflux disease: a primary care perspective. Am J Gastroenterol (2001) 0.83
Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol (2000) 0.82
Recent advances in the treatment of GERD in the elderly: focus on proton pump inhibitors. Int J Clin Pract (2005) 0.82
Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. J Clin Gastroenterol (2003) 0.82
On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion (2005) 0.82
Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux. J Voice (2002) 0.81
High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol (1999) 0.81
Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther (1999) 0.81
A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands. Clin Ther (2003) 0.81
Extraesophageal manifestations of GERD: diagnosis and therapy. Drugs Today (Barc) (2005) 0.81
Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. Aliment Pharmacol Ther (2003) 0.81
Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther (2003) 0.81
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Aliment Pharmacol Ther (2004) 0.81
Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther (2003) 0.80
Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol (2005) 0.80
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. Eur J Gastroenterol Hepatol (2002) 0.80
Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. Aliment Pharmacol Ther (1998) 0.80
Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila) (2006) 0.80
Time trends in cost of caring for people with gastroesophageal reflux disease. Am J Gastroenterol (2001) 0.80
Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol (2003) 0.80
Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion (2005) 0.79
What is the best way to manage GERD symptoms in the elderly? J Fam Pract (2006) 0.78
Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine. Eur J Gastroenterol Hepatol (2001) 0.78
Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment Pharmacol Ther (1996) 0.78
Comparison between digestive endoscopy and 24-hour esophageal pH monitoring for the diagnosis of gastroesophageal reflux esophagitis: "presentation of 100 cases". Hepatogastroenterology (2000) 0.78